Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Performance exceeded expectations driven by a 16% organic growth in Proprietary Products, specifically led by a 29% surge in the Biologics market group. High-Value Product (HVP) Components now represent 49% of total revenue, up from 46% last year, as customers increasingly shift toward advanced primary containment solutions. Operational excellence initiatives and a rapid recovery from a May cyber incident allowed the company to maintain throughput and capture high-teens growth in non-GLP-1 HVP components.